Early interim PET scan in Hodgkin lymphoma: Where do we stand?

References

• Juweid M E, Stroobants S, Hoekstra O S, Mottagy F M, Dietlein M, Guernazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22–28
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, Moller Pedersen L, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59
   PubMed Web of Science ®Google Scholar
• Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475–481
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A, Brice P, Rain J D, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376–1381
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel N G, Fields P A, Nunan T, Timothy A R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160–1168
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Hutchings M, Fields P A, O'Doherty M J, Timothy A R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005
   Web of Science ®Google Scholar
• Romer W, Hanauske A R, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464–4471
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard J P, Kuji P, Zoe H, Goldsmith S J. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018–1027
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746–3752
   PubMed Web of Science ®Google Scholar
• Skinnider B F, Mak T W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283–4297
   PubMed Web of Science ®Google Scholar
• Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48: 1626–1632
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296–1300
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Dell'Olio M, Merli F, Brugiatelli M, Stelitano C, et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica 2007; 92: 34
   Web of Science ®Google Scholar
• Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002; 13(Suppl 1)75–78
   PubMed Web of Science ®Google Scholar
• Gallamini A, Viviani S, Bonfante V, Levis A, Di Raimondo F, Merli F, et al. Early interim FDG-PET during intensified BEACOPP therapy shows a lower predictive value than during conventional ABVD chemotherapy. Haematologica 2007; 92: 71
   Web of Science ®Google Scholar
• Avigdor A, Bulvik S, Dann E J, Levi I, Perez-Avraham G, Shemtov N, et al. Combined ESCBEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: an effective regimen and low positive predictive value of early FDG-PET/CT. Haematologica 2007; 92: 66
   PubMed Web of Science ®Google Scholar
• Kasamon Y L, Wahl R L, Swinnen L J. FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. Curr Opin Oncol 2004; 16: 100–105
   PubMed Web of Science ®Google Scholar
• Dann E J, Bar-Shalom R, Tamir A, Haim N, Ben-Schachar N, Avivi I, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905–909
   PubMed Web of Science ®Google Scholar